Crucially, both PI3Kδ and BTK inhibitors exhibit their clinical effects by causing redistribution of CLL cells out of the lymph nodes into the peripheral blood, demonstrating the importance of both in CLL motility and retention (69, 70). Here, BTK is linked to B-cell chronic lymphocytic leukemia.